Please note - this article was originally published on the id21 website which has now closed. This and other articles produced by id21 were archived by Eldis in 2009 and are not actively maintained. If you find links and references which are no longer valid please email eldis@ids.ac.uk.

Drug-resistant tuberculosis: can we save money AND save lives?

The spread of drug-resistant disease is one of the biggest challenges in international health. It can cost up to one million dollars to treat a patient with drug-resistant tuberculosis (TB) in the United States. But what is the cheapest and most effective way to treat the disease? Can treatment strategies used in industrialised nations be applied in developing countries?

Researchers from the UK Universities of East Anglia and Bristol looked at different methods of treating tuberculosis in the USA and South Africa. In both countries, they found that directly observed treatment (DOT) is cheaper and more effective treatment than conventional methods which allow patients to administer the drugs themselves.

New York and Florida have reported epidemics of TB that does not respond to treatment with several different drugs. Drug-resistant TB is also spreading in Africa - rates have increased six-fold in some places. Drug-resistance can emerge when patients take drugs incorrectly or fail to complete the course of treatment. So observation of treatment may be more effective than self-administration by patients.

The study’s findings include:

Mortality levels from TB are worse in South Africa than in the USA because more of the patients are co-infected with HIV.
DOT results in fewer deaths and more complete cures because patients are more likely to complete the course of treatment.
In South Africa, conventional therapy costs twice as much as DOT. In the USA, the cost saving over conventional treatment is eight percent.
DOT saves $2215 per patient in South Africa and $1788 in the USA. It allowed 6798 patients more to be treated in South Africa than if conventional therapy had been used.
Savings with DOT are even higher for more expensive second-line drugs.

Policy implications of the research include:

Directly observed TB treatment saves money and reduces mortality in both developing and industrialised nations and should be used whenever possible.
Given limited healthcare resources, it will be particularly important to use DOT in developing countries.

Source(s):
‘Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa', International Journal of Tuberculosis and Lung Disease 5(12): 1137-1142, by P. Wilton, R. Smith, J. Coast, M. Millar and A. Karcher, 2001
Related sources: 'Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness', Journal of Health Services Research and Policy 7 (2): 111-117, by P. Wilton, R. Smith, J. Coast and M. Millar, 2002
'Anti-tuberculosis drug resistance in the world: prevalence and trends', Report No. 2, The WHO/IUATLD Global Project in Anti-tuberculosis Drug Resistance Surveillance, Geneva, 2000

Funded by: Global Forum for Health Research

id21 Research Highlight: 21 May 2002

Further Information:
Richard Smith
Health Economics, Law and Ethics Group
School of Medicine, Health Policy and Practice
University of East Anglia
Norwich
NR4 7TJ
UK

Tel: +44 (0)1603 593 617
Fax: +44 (0)1603 593 604
Contact the contributor: richard.smith@uea.ac.uk

University of East Anglia

Views expressed on these pages are not necessarily those of DfID, IDS, id21 or other contributing institutions. Articles featured on the id21 site may be copied or quoted without restriction provided id21 and originating author(s) and institution(s) are acknowledged. Copyright © 2009 IDS. All rights reserved.

id21 is funded by the UK Department for International Development. id21 is one of a family of knowledge services at the Institute of Development Studies at the University of Sussex. id21 is a www.oneworld.net partner and an affiliate of www.mediachannel.org. IDS is a charitable company, No. 877338.